Global Electronic Drug Delivery Systems Market, By Type (Electronic Infusion Pumps, Electronic Injection Pens, Electronic Auto-Injectors, Electronic Inhalers, Electronic Capsules, Others), Component (Sensors, Wireless Communicator and Antennas, Micro Pumps and Flow Regulators, Drug Reservoir, Microcontroller, Others), Connectivity (Bluetooth Low Energy (BLE), Wi-Fi, Ethernet, NB-IoT, Others), System Type (Battery-Powered Systems, Rechargeable Systems), Application (Diabetes, Asthma and Chronic Obstructive Pulmonary Disease (COPD), Multiple Sclerosis, Growth Hormone Therapy, Immunodeficiency Disease, Cardiovascular Disease, Thalassemia, Others), End User (Home Healthcare, Hospitals, Clinics, Ambulatory Centers, Others), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa) Industry Trends and Forecast to 2029.
Market Analysis and Insights : Global Electronic Drug Delivery Systems Market
Electronic drug delivery systems market is expected to gain market growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses that the market is growing with a CAGR of 8.9% in the forecast period of 2022 to 2029 and expected to reach USD 16,139.89 million by 2029.
Electronic drug delivery systems are basically electronically enabled, smart drug delivery devices are well suited to home care settings. These devices add value to outdated instruments and increase ease of administration, suitability, and movability.
The rise in the prevalence of target diseases is the major factor accelerating the growth of the electronic drug delivery systems market. Furthermore, the favorable reimbursement scenario in major markets, rapid advancements in technologies and designs, rise in the prevalence of various chronic disorders and increase in geriatric patient pool are also expected to drive the growth of the electronic drug delivery systems market. However, the strong initial spending on research and development and stringent regulations restrains the electronic drug delivery systems market, whereas, the unfavorable reimbursement structure in developing countries will challenge market growth.
In addition, increasing healthcare expenditure, and high demand for biologics and mabs will create ample opportunities for the electronic drug delivery systems market.
This electronic drug delivery systems market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on electronic drug delivery systems market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Electronic Drug Delivery Systems Market Scope and Market Size
- The electronic drug delivery systems market is segmented on the basis of type, component, connectivity, system type, application, and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
- On the basis of type, the market is segmented into electronic infusion pumps, electronic injection pens, electronic auto-injectors, electronic inhalers, electronic capsules, and others.
- On the basis of component, the market is segmented into sensors, wireless communicator and antennas, micro pumps and flow regulators, drug reservoir, microcontroller and others.
- On the basis of connectivity, the market is segmented into bluetooth low energy (BLE), Wi-Fi, ethernet, NB-IoT, and others.
- On the basis of system type, the market is segmented into battery-powered systems and rechargeable systems.
- On the basis of application, the market is segmented into diabetes, asthma and chronic obstructive pulmonary disease (COPD), multiple sclerosis, growth hormone therapy, immunodeficiency disease, cardiovascular disease, thalassemia, and others.
Electronic Drug Delivery Systems Market Country Level Analysis
The electronic drug delivery systems market is analyzed and market size insights and trends are provided by country, type, component, connectivity, system type, application, and end user as referenced above.
The countries covered in the electronic drug delivery systems market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the electronic drug delivery systems market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to increment in electronic infusion pump on a large scale. Asia-Pacific on the other hand is projected to exhibit the highest growth rate during the forecast period due to the growing incidence of asthma and heart disease with the development of the pharmaceutical industry
The country section of the electronic drug delivery systems market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The electronic drug delivery systems market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for electronic drug delivery systems market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the electronic drug delivery systems market. The data is available for historic period 2010 to 2020.
Competitive Landscape and Electronic Drug Delivery Systems Market Share Analysis
The electronic drug delivery systems market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to electronic drug delivery systems market.
The major players operating in the electronic drug delivery systems market report are AstraZeneca, Amgen Inc., Ypsomed AG, Merck KGaA, Bayer AG, Nemera, F. Hoffmann-La Roche Ltd, Teva Pharmaceuticals USA, Inc. (A Subsidiary of Teva Pharmaceutical Industries Ltd.), AptarGroup, Inc., Novo Nordisk A/S., ViCentra B.V., Medtronic, United Therapeutics Corporation, Companion Medical, Tandem Diabetes Care, Inc., Debiotech S.A., Canè S.p.A, Insulet Corporation, BD, Findair Sp. z o. o. , B. Braun Melsungen AG , and West Pharmaceutical Services, Inc., among others.